New developments in sentinel node staging in melanoma: Controversies and alternatives

Current Opinion in Oncology

Volumn 22, Issue 3, 2010, Pages 169-177

  Van Akkooi, Alexander C ^a   Voit, Christiane A ^b   Verhoef, Cornelis ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Melanoma; Metastases; Review; Sentinel node; Ultrasound

Indexed keywords

ASPIRATION CYTOLOGY; CANCER STAGING; CANCER SURVIVAL; ECHOGRAPHY; HUMAN; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE;

HUMANS; MELANOMA; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 77951491152     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328337aa78     Document Type: Review

References (117)

1. de Vries E, Coebergh JW. Melanoma incidence has risen in Europe. BrMed J 2005; 331:698. (Pubitemid 41374854)
2. de Vries E, Houterman S, Janssen-Heijnen ML, et al. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands. Ann Oncol 2007; 18:1110-1116.
3. de Vries E, Schouten LJ, Visser O, et al. Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient? Eur J Cancer 2003; 39:1439-1446.
4. Downing A, Yu XQ, Newton-Bishop J, et al. Trends in prognostic factors and survival from cutaneous melanoma in Yorkshire, UK and New South Wales, Australia between 1993 and 2003. Int J Cancer 2008; 123:861-866.
5. Lasithiotakis KG, Leiter U, Eigentler T, et al. Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed? Cancer 2007; 109:1174-1182.
6. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009; 20 (Suppl 6):vi1-vi7.
7. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
8. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147:62-70.
9. Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220:759-767.
10. Hochwald SN, Coit DG. Role of elective lymph node dissection in melanoma. Semin Surg Oncol 1998; 14:276-282.
11. Bagley FH, Cady B, Lee A, et al. Changes in clinical presentation and management of malignant melanoma. Cancer 1981; 47:2126-2134.
12. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982; 196:677-684.
13. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979; 86:343-351.
14. Binder M, Pehamberger H, Steiner A, et al. Elective regional lymph node dissection in malignant melanoma. Eur J Cancer 1990; 26:871-873.
15. Coates AS, Ingvar CI, Petersen-Schaefer K, et al. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991. J Am Coll Surg 1995; 180:402-409.
16. Crowley NJ, Seigler HF. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. Cancer 1990; 66:2522-2527.
17. Drepper H, Kohler CO, Bastian B, et al. Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients. Cancer 1993; 72:741-749.
18. Elder DE, Guerry Dt, VanHorn M, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985; 56:413-418.
19. Karakousis CP, Kachrimanidis S, Rao U, et al. Changes in survival with clinical stage I malignant melanoma. J Surg Oncol 1987; 34:155-159.
20. McCarthy WH, Shaw HM, Milton GW. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet 1985; 161:575-580.
21. Milton GW, Shaw HM, McCarthy WH, et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982; 69:108-111.
22. Reintgen DS, Cox EB, McCarty KS Jr, et al. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983; 198:379-385.
23. Rompel R, Garbe C, Buttner P, et al. Elective lymph node dissection in primary malignant melanoma: a matched-pair analysis. Melanoma Res 1995; 5:189-194.
24. Slingluff CL Jr, Stidham KR, Ricci WM, et al. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg 1994; 219:120-130.
25. Wanebo HJ, Woodruff J, Fortner JG. Malignant melanoma of the extremities: a clinicopathologic study using levels of invasion (microstage). Cancer 1975; 35:666-676.
26. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977; 297:627-630.
27. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer 1978; 41:948-956.
28. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224:255-263; discussion 263-266
29. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998; 351:793-796.
30. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mappingforearly stage melanoma.Arch Surg 1992; 127:392-399.
31. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977; 39:456-466.
32. Gould EA, Winship T, Philbin PH, et al. Observations on a 'sentinel node' in cancer of the parotid. Cancer 1960; 13:77-78.
33. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307-1317
34. UrenRF,Howman-GilesR,ChungDK,etal.Thereproducibilityinroutineclinical practice of sentinel lymph node identification by preoperative lymphoscintigra-phyinpatientswithcutaneousmelanoma.AnnSurgOncol2007;14:899-905.
35. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
36. Carlson GW, Murray DR, Lyles RH,et al. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol 2003; 10:575-581.
37. Carlson GW, Page AJ, Cohen C, et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg 2008; 248:378-386.
38. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006; 24:4464-4471.
39. Doubrovsky A, De Wilt JH, Scolyer RA, et al. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Ann Surg Oncol 2004; 11:829-836.
40. Estourgie SH, Nieweg OE, Valdes Olmos RA, et al. Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years. Ann Surg Oncol 2003; 10:681-688.
41. Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 2008; 26:4296-4303
42. GershenwaldJE,ThompsonW,MansfieldPF,etal.Multiinstitutionalmelanoma lymphatic mapping experience: the prognostic value of sentinel lymph node statusin612 stageIorIImelanoma patients.J Clin Oncol 1999; 17:976-983.
43. Guggenheim M, Dummer R, Jung FJ, et al. The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma: a retrospective analysis of 392 cases. Br J Cancer 2008; 98:1922-1928.
44. Kettlewell S, Moyes C, Bray C, et al. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. BMJ 2006; 332:1423.
45. Koskivuo I, Talve L, Vihinen P, et al. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Ann Surg Oncol 2007; 14:3566-3574.
46. Kretschmer L, Beckmann I, Thoms KM, et al. Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas. Eur J Cancer 2005; 41:531-538.
47. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, et al. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol 2006; 13:1655-1663.
48. Sassen S, Shaw HM, Colman MH, et al. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at asingle center. Ann Surg Oncol 2008; 15:630-637.
49. Scheri RP, Essner R, Turner RR, et al. Isolated tumor cells in the sentinel node affect long-term prognosisofpatients with melanoma. Ann Surg Oncol 2007; 14:2861-2866.
50. van Akkooi AC, de Wilt JH, Verhoef C, et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 2006; 42:372-380.
51. Vuylsteke RJ, van Leeuwen PA, Statius Muller MG, et al. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 2003; 21:1057-1065.
52. Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol 2005; 12:429-439.
53. Cecchi R, Buralli L, Innocenti S, et al. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol 2007; 34:512-515.
54. Hershko DD, Robb BW, Lowy AM, et al. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol 2006; 93:279-285.
55. Koskivuo I, Suominen E, Niinikoski J, et al. Sentinel node metastasectomy in thin or1-mm melanoma. Langenbecks Arch Surg. 2005, 390. 403-407
56. Ranieri JM, Wagner JD, Wenck S, et al. The prognostic importanceof sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 2006; 13:927-932.
57. Wong SL, Brady MS, Busam KJ, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006; 13:302-309.
58. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg 2008; 143:892-899; discussion 899-900.
59. Cochran AJ, Roberts A, Wen DR, et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours. Pathology 2004; 36:478-484.
60. Cochran AJ, Balda BR, Starz H, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lympha-denectomy in cutaneous malignancies. Cancer 2000; 89:236-241.
61. Scolyer RA, Murali R, McCarthy SW, et al. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 2008; 25:100-111.
62. Cook MG, Green MA, Anderson B, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200:314-319.
63. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistolo-gical study. Am J Surg Pathol 1988; 12:612-618.
64. Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, et al. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer 2004; 100:1683-1691.
65. Gietema HA, Vuylsteke RJ, de Jonge IA, et al. Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol 2004; 57:618-620.
66. Spanknebel K, Coit DG, Bieligk SC, et al. Characterization of micrometa-static disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol 2005; 29:305-317.
67. Chao C, Wong SL, Ross MI, et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002; 184:520-524; discussion 525.
68. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16:2253-2260.
69. Gogel BM, Kuhn JA, Ferry KM, et al. Sentinel lymph node biopsy for melanoma. Am J Surg 1998; 176:544-547.
70. Zogakis TG, Essner R, Wang HJ, et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg 2005; 140:865-871; discussion 871-872
71. Rossi CR, Pasquali S, Mocellin S. Actual false-negative rate prompts the routine use of ultrasound scan before and after sentinel node biopsy in melanoma. Ann Surg Oncol 2008; 15:2976-2977.
72. Jansen L, Nieweg OE, Peterse JL, et al. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000; 87:484-489. (Pubitemid 30192962)
73. Nieweg OE, Estourgie SH. What is a sentinel node and what is a false-negative sentinel node? Ann Surg Oncol 2004; 11:169S-173S.
74. Wasserberg N, Tulchinsky H, Schachter J, et al. Sentinel-lymph-node biopsy (SLNB) for melanoma is not complication-free. Eur J Surg Oncol 2004; 30:851-856.
75. Scolyer RA, Murali R, Satzger I, et al. The detection and significance of melanoma micrometastases in sentinel nodes. Surg Oncol 2008; 17:165-174.
76. ClinicalTrials.gov. Multicenter Selective Lymphadenectomy Trial (MSLT); NCT00275496; 2008.
77. Cochran AJ, Thompson JF. Lymphatic mapping and sentinel node biopsy: the data unclouded by speculation. Arch Dermatol 2008; 144:687-688; author reply 688-689
78. Morton DL, Cochran AJ, Thompson JF. The rationale for sentinel-node biopsy in primary melanoma. Nat Clin Pract Oncol 2008; 5:510-511.
79. Morton DL, Elashoff R. Sentinel node biopsy: facts to clear the alleged clouds. Arch Dermatol 2008; 144:685-686; author reply 687.
80. Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol 2008; 15:670-673.
81. Gershenwald JE, Ross MI. Is sentinel-node biopsy superior to nodal observation in melanoma? Nat Clin Pract Oncol 2007; 4:278-279.
82. De Giorgi V, Leporatti G, Massi D, et al. Sentinel lymph nodes in melanoma patients: evaluating the evidence. Oncology 2006; 71:460-462.
83. Gonzalez U. Cloud over sentinel node biopsy: unlikely survival benefit in melanoma. Arch Dermatol 2007; 143:775-776.
84. Kanzler MH. The current status of evaluation and treatment of high-risk cutaneous melanoma: therapeutic breakthroughs remain elusive. Arch Dermatol 2007; 143:785-787.
85. Thomas JM. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 2008; 5:18-23.
86. van Akkooi AC, Bouwhuis MG, de Wilt JH, et al. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma. Br J Surg 2007; 94:1293-1299.
87. van Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol. 2006, 17. 1578-1585
88. van Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008; 248:949-955.
89. Govindarajan A, Ghazarian DM, McCready DR, et al. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol 2007; 14:906-912.
90. Scolyer RA, Murali R, Gershenwald JE, et al. Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Ann Oncol 2007; 18:806-808.
91. Ranieri JM, Wagner JD, Azuaje R, et al. Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol 2002; 9:975-981.
92. Reeves ME, Delgado R, Busam KJ, et al. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 2003; 10:27-31.
93. Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classifica-tion: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004; 11:162S-168S.
94. Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 2004; 17:747-755.
95. Dewar DJ, Newell B, Green MA, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 2004; 22:3345-3349.
96. Vuylsteke RJ, Borgstein PJ, van Leeuwen PA, et al. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol 2005; 12:440-448.
97. Sabel MS, Griffith K, SondakVK, etal. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 2005; 201:37-47.
98. Pearlman NW, McCarterMD, Frank M, etal. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg 2006; 192:878-881.
99. Satzger I, Volker B, Al Ghazal M, et al. Prognostic significance of histo-pathological parameters in sentinel nodes of melanoma patients. Histo-pathology 2007; 50:764-772. (Pubitemid 46683934)
100. Debarbieux S, Duru G, Dalle S, et al. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol 2007; 157:58-67.
101. Roka F, Mastan P, Binder M, etal. Prediction of nonsentinel node status and outcome in sentinel node-positive melanoma patients. Eur J Surg Oncol 2008; 34:82-88.
102. Frankel TL, Griffith KA, Lowe L, et al. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? Ann Surg Oncol 2008; 15:2403-2411.
103. van Akkooi ACJ, Rutkowski P, van der Ploeg IM, et al. Long-term follow-up of patients with minimal sentinel node tumor burden (<0.1 mm) according to Rotterdam criteria: a study of the EORTC melanoma group. J Clin Oncol Supp. 2009, 27. 15s, Abstract 9005
104. van Akkooi ACJ, Rutkowski P, van der Ploeg IM, et al.Excellent long-term survival of patients with minimal sentinel node tumor burden
105. MuraliR, Cochran AJ, Cook MG,et al. Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. Cancer 2009; 115:5026-5037.
106. van Akkooi AC, Spatz A, Eggermont AM, et al. Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. Eur J Cancer 2009; 45:2736-2742.
107. van Akkooi AC, de Wilt JH, Verhoef C, et al. The Rotterdam criteria for sentinel node tumor load: the simplest prognostic factor? J Clin Oncol 2008; 26:6011; author reply 6012.
108. de Kanter AY, van Eijck CH, van Geel AN, et al. Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg 1999; 86:1459-1462.
109. Leboulleux S, Girard E, Rose M, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92:3590-3594.
110. Rossi CR, Seno A, Vecchiato A, et al. The impact of ultrasound scanning in the staging and follow-up of patients with clinical stage I cutaneous melanoma. Eur J Cancer 1997; 33:200-203.
111. Voit C, Mayer T, Kron M, et al. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients. Cancer 2001; 91:2409-2416.
112. Rossi CR, Mocellin S, Scagnet B, etal. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol 2003; 83:80-84.
113. Starritt EC, Uren RF, Scolyer RA, et al. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol 2005; 12:18-23.
114. van Rijk MC, Teertstra HJ, Peterse JL, et al. Ultrasonography and fine-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy. Ann Surg Oncol 2006; 13:1511-1516.
115. Voit CA, van Akkooi ACJ, Schafer-Hesterberg G, et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. J Clin Oncol 2010. [Epub ahead of print]
116. Voit CA, van Akkooi AC, Schafer-Hesterberg G, et al. Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol 2009; 27:4994-5000.
117. van Akkooi AC, Voit CA, Verhoef C, et al. Potential cost-effectiveness of US-guided FNAC in melanoma patients as a primary procedure and in follow-up. Ann Surg Oncol 2009. [Epub ahead of print]